Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

FDA approves SERM for preventing postmenopausal osteoporosis

Dec. 11, 1997

Potential new male contraceptive under development in China

Dec. 11, 1997

Sparta acquires rights to PZG

Dec. 10, 1997

TH-9507 proceeds to toxicological studies

Dec. 10, 1997

BioTime reports preliminary phase III data from Hextend trial

Dec. 9, 1997

Lilly discovers highly potent and selective NPY Y1 receptor antagonists

Dec. 9, 1997

NPS and SmithKline Beecham sign additional extension of osteoporosis agreement

Dec. 9, 1997

HMR begins phase II trial with GA-EPO

Dec. 8, 1997

Sanofi in-licenses antidiabetic drug from Bayer

Dec. 4, 1997

New inhibitor of inflammatory bone resorption presented at Tokyo congress

Dec. 4, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...